TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Heart Rate Variability Standard Deviation of NN Intervals (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baroreflex Sensitivity High Frequency (HF) Alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baroreflex Sensitivity Sequence Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoperitoneum incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Periodontal ligament space width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale (NRS) pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pancreatic fistula grade A/B/C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pancreatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance in balance beam walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of tracheal-bronchial collapse area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: therapeutic maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Days Used Primary Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Dollar Amount Spent Per Day on Primary Drug
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Number of Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Drinks Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of Laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful revascularization without major adverse cardiocerebral events (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained Virological Response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Attachment Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient expectations of breast-conserving therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Posturography measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth differentiation factor-9 (GDF-9) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone morphogenetic protein-15 (BMP-15) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicle-stimulating hormone (FSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in maintained weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of fibrin/clot formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantity of Blood Vessels and Capillaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Quantity of macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transfusion peroperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Binary treatment outcome in terms of remission from depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving Sustained Viral Response (SVR) (Stage 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in cocaine-reinforced behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on distance walked in the six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good/Moderate European League Against Rheumatism Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility (recruitment number)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in MADRS-10 Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in Glasgow coma score (GCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cerebral vascular accident (CVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants experiencing ocular and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Spasticity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Shock prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-patient hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacodynamic change using FLT-PET/CT scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response of axitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Early Neurologic Deterioration (END)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gene expression levels of LncRNA H19 & IGF-1R mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra and inter-operator reproducibility of PET-MRI mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with more than 1 grade improvement in the Hughes functional grading scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Strain in the affected coronary artery stenosis myocardial segments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-inf Of Danicopan Prototype PIC 1 Formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax Of Danicopan Prototype PIC 1 Formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax Of Danicopan Prototype PIC 1 Formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's Ability to Use the SSEC
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adherence of the SSEC System to Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Female sexual function index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in percentage short interval intracortical inhibition (SICI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Angiographic Assessment of Vessel Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedural Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Breastfeeding intensity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of C1-esteraseremmer-N
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-effect of C1-esteraseremmer-N
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Injection site tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative marginal reflex distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biochemical response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximal clot firmness of EXTEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pattern of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to goals concerning risk factors, lifestyle modifications and pharmacological therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Remission or improvement of comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Craniovertebral angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of moderate to severe Persistent Post-Surgical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV related stigma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Ulcer Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implicative dilemma
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Dilemmatic construct
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Time to cardiovascular death or non-fatal MI
Endpoint domain: Mortality/survival
Primary endpoint: Genetic mutations of patients with stromal tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Compassion fatigue of participants
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resilience of participants
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Efficacy of participants
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Axons With Abnormal Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to occurrence of gastric and/or duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: cumulative proportion of deep venous thrombosis or pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Accuracy of sentinel node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative Predictive Value of sentinel node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Score changes of Melbourne Assessment 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior chamber depth (ACD) in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transplantation failure
Endpoint domain: Mortality/survival
Primary endpoint: Functional outcome according to the modified Rankin scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HIV-1 RNA copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in intensity of Suicidal thoughts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of suicidal thoughts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self reported emotion regulation ability through Difficulties in Emotion Regulation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in rate of subjects with persistence of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of AL-335 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of AL-335 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total daily symptoms and medications score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in plasma phosphate in mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to tooth color satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prognostic impact of ctDNA positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostasis from the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stoppage of haematemesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stoppage of melena
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Esophageal pressure measurements from upright to prone position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Esophageal pressure measurements from upright to supine position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Hospital Admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With Emergency Department Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With Urgent Clinic Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Immediate Unsolicited Adverse Events (AE) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Immunotherapy-induced colitis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with confirmed etiological diagnosis of tonsillitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of fever (body temperature ≥ 38.0°C)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events frequency, severity and nature
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pain Assessed by Visual Analogue Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Post-Operative Trichiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-Minute Sit to Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and toxicity of nelfinavir
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of nelfinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical course of untreated XLHED individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotype of untreated XLHED individuals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density Change in Lumber Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density Change in Collum Femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density Change in Trochiter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with clinical improvement on a 7-point ordinal scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the sum of the UPDRS Parts II and III total scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Doubling of serum creatinine, ESRD or death
Endpoint domain: Mortality/survival
Primary endpoint: In-stent percent diameter stenosis (%DS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exhaled propofol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Addenbrooke cognitive battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: serum procalcitonin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum-reactive protein values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lactate values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of LDS signals as Power and Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and Specificity of the Exact CRC Screening Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three dimensional gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcome Questionnaire-45 (OQ-45)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prostate-Specific Antigen (PSA) Response Greater Than or Equal to 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CADIS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Successful completion of enrollment and stress testing lab visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximal voluntary force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anterior Insula Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Accumbens Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Amygdala Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in dACC Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in mOFC Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in rACC Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Itraconazole and its metabolites level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semen Clearance of Tenofovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semen Clearance of Emtricitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semen Clearance of Tenofovir Diphosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semen Clearance of Emtricitabine Triphosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral Blood Mononuclear Cell Clearance of Tenofovir Diphosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Caries occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression from EM to CM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Achieve CR or PR by Day 28 of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Developed Steroid Refractory GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of devices and packages of asthma medication used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IPPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Narcotic Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Vaginal relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Composite Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDA score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in supine pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum clot formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reproducibility of radiation treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disruptive Behavior Diagnostic Observation Schedule (DB DOS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PROMIS Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention or delay of Type 2 Diabetes Mellitus (DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum melatonin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum nitric oxide (NO) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health Self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in risk of early mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in acute service use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence of any dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: screening proposal rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: patient acceptance rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: serological achievement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes